97 related articles for article (PubMed ID: 12614244)
1. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer?
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
BJU Int; 2003 Jan; 91(1):23-9. PubMed ID: 12614244
[TBL] [Abstract][Full Text] [Related]
2. Role of isotope selection in long-term outcomes in patients with intermediate-risk prostate cancer treated with a combination of external beam radiotherapy and low-dose-rate interstitial brachytherapy.
Wernicke AG; Shamis M; Yan W; Trichter S; Sabbas AM; Goltser Y; Christos PJ; Brennan JS; Parashar B; Nori D
Urology; 2012 May; 79(5):1098-104. PubMed ID: 22546388
[TBL] [Abstract][Full Text] [Related]
3. Fewer systematic prostate core biopsies in clinical stage T1c prostate cancer leads to biochemical recurrence after brachytherapy as monotherapy.
Ozawa Y; Nohara S; Nakamura K; Hattori S; Yagi Y; Nishiyama T; Yorozu A; Monma T; Saito S
Prostate; 2024 Apr; 84(5):502-510. PubMed ID: 38173289
[TBL] [Abstract][Full Text] [Related]
4. Trimodality Therapy With Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP/TRIGU0907).
Yorozu A; Namiki M; Saito S; Egawa S; Yaegashi H; Konaka H; Momma T; Fukagai T; Tanaka N; Ohashi T; Takahashi H; Nakagawa Y; Kikuchi T; Mizokami A; Stone NN
Int J Radiat Oncol Biol Phys; 2024 Feb; 118(2):390-401. PubMed ID: 37802225
[TBL] [Abstract][Full Text] [Related]
5. The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort.
Nabhan M; Kim SP; Shah ND; Bagniewski SM; Shi Q; Karnes RJ; Weight CJ; Davis BJ; Kohli M; Tilburt JC
Mayo Clin Proc; 2012 Jun; 87(6):540-7. PubMed ID: 22677074
[TBL] [Abstract][Full Text] [Related]
6. A low prostate specific antigen predicts a worse outcome in high but not in low/intermediate-grade prostate cancer.
Fankhauser CD; Parry MG; Ali A; Cowling TE; Nossiter J; Sujenthiran A; Berry B; Morris M; Aggarwal A; Payne H; van der Meulen J; Clarke NW
Eur J Cancer; 2023 Mar; 181():70-78. PubMed ID: 36641896
[TBL] [Abstract][Full Text] [Related]
7. Conditional Risks of Biochemical Failure and Prostate Cancer-Specific Death in Patients Undergoing External Beam Radiotherapy: A Secondary Analysis of 2 Randomized Clinical Trials.
Alexander GS; Krc RF; Assif JW; Sun K; Molitoris JK; Tran P; Rana Z; Bentzen SM; Mishra MV
JAMA Netw Open; 2023 Sep; 6(9):e2335069. PubMed ID: 37751207
[TBL] [Abstract][Full Text] [Related]
8. The influence of Gleason score ≤ 6 histology on the outcome of high-risk localized prostate cancer after modern radiotherapy.
Yamazaki H; Suzuki G; Masui K; Aibe N; Kimoto T; Yamada K; Okihara K; Hongo F; Okumi M; Shiraishi T; Fujihara A; Yoshida K; Nakamura S; Kato T; Hashimoto Y; Okabe H
Sci Rep; 2024 Apr; 14(1):8011. PubMed ID: 38580670
[TBL] [Abstract][Full Text] [Related]
9. Comparison of EBRT and I-125 seed brachytherapy concerning outcome in intermediate-risk prostate cancer.
Moll M; Renner A; Kirisits C; Paschen C; Zaharie A; Goldner G
Strahlenther Onkol; 2021 Nov; 197(11):986-992. PubMed ID: 34351453
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric MRI as a Predictor of PSA Response in Patients Undergoing Stereotactic Body Radiation Therapy for Prostate Cancer.
Rayn K; Deutsch I; Jeffers B; Lee A; Lavrova E; Gallitto M; Mayeda M; Hwang M; Yu J; Spina C; Koutcher L
Adv Radiat Oncol; 2024 Mar; 9(3):101408. PubMed ID: 38304110
[TBL] [Abstract][Full Text] [Related]
11. Is it necessary to cure prostate cancer when it is possible? (Understanding the role of prostate inflammation resolution to prostate cancer evolution).
Wheeler RE
Clin Interv Aging; 2007; 2(1):153-61. PubMed ID: 18044088
[TBL] [Abstract][Full Text] [Related]
12. MANAGEMENT OF PROSTATE CANCER IN ACCRA, GHANA.
Yeboah ED; Hsing AW; Mante S; Mensah JE; Kyei MY; Yarney J; Vanderpuye V; Beecham K; Tettey Y; Biritwum RB; Adjei AA; Gyasi R; Asante K; Ampadu KN; Klufio GO; Gepi-Attee S; Owoo C; Kwami D; Ahiaku ; Pandra R; Cook MB
J West Afr Coll Surg; 2016; 6(4):31-65. PubMed ID: 29181364
[TBL] [Abstract][Full Text] [Related]
13. Early change in apparent diffusion coefficient as a predictor of response to neoadjuvant androgen deprivation and external beam radiation therapy for intermediate- to high-risk prostate cancer.
Franco FB; Leeman JE; Fedorov A; Vangel M; Fennessy FM
Clin Radiol; 2024 Apr; 79(4):e607-e615. PubMed ID: 38302377
[TBL] [Abstract][Full Text] [Related]
14. External beam radiation for the treatment of castration-resistant prostate cancer following primary hormonal therapy with androgen ablation: Analysis and outcome of 21 patients.
Kuusk T; Pulliainen K; Vaarala MH
Mol Clin Oncol; 2017 Mar; 6(3):428-432. PubMed ID: 28451427
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Three Groups of Patients Having Low Dose Rate Prostate Brachytherapy: Prostate-Specific Antigen Failure and Overall Survival.
Booher J; Domenig P; Goldman B; Campbell T; Verdecchia K; Boura JA; Chuba PJ
Cureus; 2021 Sep; 13(9):e18185. PubMed ID: 34707958
[TBL] [Abstract][Full Text] [Related]
16. Long-term tumor control after brachytherapy for base-of-prostate cancer.
Samuelian JM; Swanson DA; Kudchadker RJ; Pugh TJ; Kuban DA; Lee AK; Choi S; Nguyen QN; Bruno TL; Frank SJ
J Contemp Brachytherapy; 2011 Dec; 3(4):183-7. PubMed ID: 23346126
[TBL] [Abstract][Full Text] [Related]
17. Gleason score stratification according to age at diagnosis in 1028 men.
Pepe P; Pennisi M
Contemp Oncol (Pozn); 2015; 19(6):471-3. PubMed ID: 26843845
[TBL] [Abstract][Full Text] [Related]
18. An early-detection programme for prostate cancer in Saudi men: A call from a tertiary-care centre in the Eastern province.
Osman E; Gomha MA; Harb A; Aldayel A; Aloraifi I; Almousa R; Khan I
Arab J Urol; 2014 Sep; 12(3):187-91. PubMed ID: 26019947
[TBL] [Abstract][Full Text] [Related]
19. The prognosis of patients with prostate cancer receiving permanent seed implantation stratified by prostate volume: Should we be reluctant to treat with brachytherapy because of a very small prostate (<15 cc)?
Masui K; Katayama N; Yorozu A; Kikuchi T; Higashide S; Kojima S; Saito S
Radiother Oncol; 2023 Nov; 188():109855. PubMed ID: 37597804
[TBL] [Abstract][Full Text] [Related]
20. Clinical, Histopathological, and Prognostic Characteristics of Patients with Prostate Cancer in Lubumbashi, Democratic Republic of Congo.
Mbey PM; Mukuku O; Arung WK; Tengu GK; Amisi NL; Kyabu VK; Odimba EFK; Tshilombo FK
Prostate Cancer; 2020; 2020():5286929. PubMed ID: 33376609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
